2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.08 Concannon

PP01.08 Concannon - Poster

Pdf Summary

The document presents findings from a Phase I clinical trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor, in patients with HER2 mutation-positive solid tumors, specifically non-small cell lung cancer (NSCLC). The study aims to address the need for targeted therapy for patients with HER2 mutations in solid tumors. Zongertinib, a novel tyrosine kinase inhibitor, selectively targets HER2 mutations while sparing wild-type EGFR. The trial demonstrated high response rates in NSCLC patients with HER2 mutations, with a median duration of response exceeding a year. The drug was well-tolerated, with low rates of adverse events and no treatment discontinuations. The study indicated promising outcomes, with an objective response rate of 74% and a disease control rate of 91% in the Phase Ib cohort. The interim futility analysis showed encouraging results, leading to the continuation of the trial across all cohorts. Overall, the trial suggests zongertinib as a potential effective treatment for patients with HER2 aberrations, particularly those with NSCLC and HER2 mutations. Further data and analysis from the trial will provide valuable insights into the efficacy and safety profile of zongertinib in this patient population.

Keywords

Phase I clinical trial

Zongertinib

BI 1810631

HER2-specific tyrosine kinase inhibitor

HER2 mutation-positive solid tumors

Non-small cell lung cancer (NSCLC)

Targeted therapy

Novel tyrosine kinase inhibitor

Objective response rate

Disease control rate